Prodeon Medical Receives FDA 510(k) Clearance for the Urocross(R) Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.
MassDevice

Prodeon gets FDA clearance for BPH-treating nitinol implant

Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...
Nasdaq

Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander

IRVINE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic ...